For decades, a diagnosis of type 2 diabetes was considered an irreversible, progressive condition. While clinical trials like DiRECT showed that weight loss can normalize blood sugar in older adults, younger individuals facing early-onset type 2 diabetes encounter a far more aggressive disease course. Diagnosed between ages 18 and 45, these individuals typically experience accelerated loss of pancreatic beta-cell function and heightened cardiovascular risk.
Now, a landmark multi-center randomized controlled trial published in The Lancet Regional Health – Americas demonstrates that this trajectory can be reversed. The RESET for Remission trial found that combining a low-energy diet replacement with structured resistance and aerobic exercise enabled more than half of participating young adults to achieve clinical diabetes remission within six months, while shielding lean muscle mass from the wasting typical of rapid weight loss.
What Is the RESET for Remission Trial?
Co-led by investigators at McGill University Health Centre and the University of Leicester, the RESET trial evaluated 96 adults aged 18 to 45 who had lived with type 2 diabetes for under six years and were not taking insulin. Participants were randomized into two groups:
- Intensive Lifestyle Intervention (n=50): Followed a two-phase protocol. During weeks 1 to 12, participants consumed an 800-to-900 kcal/day nutritionally complete meal-replacement formula alongside supervised exercise sessions twice weekly, plus one weekly home session. In weeks 13 to 24, they reintroduced whole foods to transition into weight maintenance while continuing exercise.
- Usual Care Control (n=46): Received standard guideline-directed diabetes care, including routine consultations, dietary education, and standard pharmaceutical management.
The Core Findings: Remission and Organ Fat Clearance
The primary outcome was diabetes remission at 24 weeks. Under consensus criteria from the American Diabetes Association and EASD, remission was defined as achieving an HbA1c below 6.5% sustained for at least 12 weeks without glucose-lowering drugs.
At 24 weeks, 54% (27 of 50 participants) in the intensive lifestyle group achieved complete diabetes remission, compared to just 4% (2 of 46 participants) in usual care. This twelve-fold increase underscores the therapeutic power of structured early intervention.
Volumetric magnetic resonance imaging (MRI) revealed striking shifts in internal body composition:
- Visceral Fat Reduction: Intervention participants averaged a 24.3% drop in visceral adipose tissue around abdominal organs.
- Liver Fat Clearance: Absolute liver fat decreased by over 9%, substantially lowering hepatic steatosis—a primary driver of systemic insulin resistance.
- Muscle Mass Preservation: While participants shed an average of 13.5 kilograms (nearly 30 pounds), MRI confirmed that skeletal muscle volume and strength were preserved relative to body mass.
- Blood Pressure Improvements: Among participants with baseline hypertension, 52% achieved normal blood pressure without medications.
How Resistance Training Protects Skeletal Muscle
A distinctive feature of the RESET protocol was integrating progressive resistance training alongside caloric deficit. During severe energy restriction, the body catabolizes both adipose tissue and lean skeletal muscle, with crash diets often losing 25% to 30% of total mass from muscle tissue.
Skeletal muscle absorbs roughly 80% of post-meal blood glucose. Losing muscle impairs long-term metabolic flexibility. By pairing resistance training—including leg presses and rows—with aerobic intervals, the trial stimulated muscle protein synthesis. This stimulus protected functional muscle tissue while hepatic and visceral fat stores were cleared. This mechanism mirrors clinical insights on how to reverse prediabetes with diet and exercise, where muscular capacity supports long-term glucose handling.
Clinical Results Breakdown
The table below summarizes clinical outcomes observed at 24 weeks in the RESET trial:
| Clinical Parameter | Intensive Lifestyle Group | Usual Care Control | Clinical Significance |
|---|---|---|---|
| Diabetes Remission Rate | 54% (27/50) | 4% (2/46) | Primary endpoint (p < 0.0001) |
| Average Weight Loss | -13.5 kg (-29.8 lbs) | -1.2 kg (-2.6 lbs) | Substantial energy deficit response |
| Visceral Fat Reduction (MRI) | -24.3% | -1.8% | Targeted organ fat clearance |
| Liver Fat Reduction (MRI) | >9% absolute drop | Minimal change | Restores hepatic insulin sensitivity |
| Lean Muscle Mass Status | Preserved volume & strength | Unchanged | Resistance training prevented wasting |
| Hypertension Remission | 52% normotensive off drugs | 11% | Cardiovascular risk reduction |
Source: Data adapted from Dasgupta K, Yates T, et al. The Lancet Regional Health – Americas (2026), DOI: 10.1016/j.lana.2026.101664.
Study Limitations and Open Questions
While encouraging, clinical researchers highlight important considerations:
- Follow-Up Duration: The study reported outcomes at 24 weeks. Long-term durability over 2 to 5 years depends on preventing weight regain through sustained dietary habits.
- Supervision Needs: The intervention included professional coaching from exercise physiologists and dietitians, which may not be readily accessible in every healthcare setting.
- Target Population: Enrollees were younger adults not using insulin with preserved beta-cell reserves. These findings cannot be generalized to late-stage disease or severe insulin deficiency.
- Remission vs. Cure: Remission is not a permanent cure. As noted by the National Institute of Diabetes and Digestive and Kidney Diseases, underlying beta-cell vulnerability remains, meaning weight regain can cause diabetes recurrence.
The Broader Context: Global Metabolic Health
According to the World Health Organization, diabetes prevalence continues to increase globally, driven by physical inactivity and energy-dense diets. Early-onset diabetes carries significant lifetime risk because it develops during prime working years.
Recent studies on muscle biology, including research on how Miro1 and exercise restore muscle cell function, show that skeletal muscle acts as an endocrine organ. Clearing ectopic lipid stores—as discussed in research on hidden muscle fat and cardiometabolic risk—addresses the cellular drivers of metabolic disease rather than solely managing symptoms.
Key Takeaways for Readers
- Act Early: Intervening shortly after diagnosis provides the greatest opportunity for beta-cell recovery and medication-free remission.
- Prioritize Muscle: Combine any dietary deficit with resistance training to maintain lean tissue and metabolic capacity.
- Work With Professionals: Very-low-energy diets and medication adjustments require medical oversight to avoid hypoglycemia or hypotension.
- Focus on Long-Term Habits: Reintroducing wholesome, unprocessed foods and maintaining daily physical activity are vital for sustained remission.
Related Reading
- How to Reverse Prediabetes: Diet and Exercise That Work
- Insulin Resistance: The Silent Driver of Chronic Disease
- Miro1 and Insulin Resistance: How Exercise Restores Muscle Cells
- Hidden Muscle Fat: A Silent Cardiometabolic Risk
Sources and Further Reading
- Dasgupta K, Yates T, et al. Low energy diet plus supervised exercise vs. usual care alone in people with early-onset type 2 diabetes (RESET for Remission): a randomised, open-label, blinded-endpoint efficacy trial. The Lancet Regional Health – Americas (2026). DOI: 10.1016/j.lana.2026.101664.
- American Diabetes Association. Definition and Interpretation of Remission in Type 2 Diabetes. Available from: American Diabetes Association.
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Type 2 Diabetes Overview, Causes, and Management. Available from: NIH NIDDK.
- World Health Organization (WHO). Diabetes Fact Sheet and Global Burden. Available from: World Health Organization.
Disclosure: This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before making changes to your health regimen.